Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine

Molecular Pharmacology

Volumn 49, Issue 5, 1996, Pages 882-890

  Balzarini, Jan ^a   Pelemams, Heidi ^a   Pérez Pérez, Maria Jesus ^b   San Félix, Ana ^b   Camarasa, Maria José ^b   De Clercq, Erik ^a   Karlsson, Anna ^c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 (2 METHYL 3 FURYLTHIOXOMETHYLAMINO)BENZOIC ACID CYCLOPENTYL ESTER; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 3' (TERT BUTYLOXYIMINOMETHYL) 4' CHLORO 2 METHYLFURANTHIOCARBOXANILIDE; 9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ANILIDE; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EMIVIRINE; LAMIVUDINE; NEVIRAPINE; PIPERAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOCARBOXANILIDE; THYMIDINE DERIVATIVE; UC 10; UC 42; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG MIXTURE; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTANT;

BASE SEQUENCE; CELLS, CULTURED; DNA PRIMERS; DRUG SYNERGISM; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION; ZALCITABINE;

EID: 0029922342     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Cooney, D. A., M. Dalal, H. Mitsuya, J. B. McMahon, M. Nadkarni, J. Balzarini, S. Broder, and D. G. Johns. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol. 35:2065-2068 (1986).
2. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. Nusinoff Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337 (1986).
3. Ahluwalia, G., D. A. Cooney, H. Mitsuya, A. Fridland, K P. Flora, Z. Hao, M. Dalal, S. Broder, and D. G. Johns. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HW infectivity. Biochem. Pharmacol. 36:3797-3801 (1987).
4. St. Clair, M. H., C. A. Richards, T. Spector, K. J. Weinhold, W. H. Miller, A. J. Langlois, and P. A. Furman. 3′-Azido-3-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 31:1972-1977 (1987).
5. Balzarini, J., P. Herdewijn, and E. De Clercq. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264:6127-6133 (1989).
6. Soudeyns, H , X.-J. Yao, Q. Gao, B. Belleau, J.-L. Kraus, N. Nguyen-Ba, B. Spira, and M. A. Wainberg. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 35:1386-1390 (1991).
7. Coates, J. A. V., N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson, R. Storer, J. M. Cameron, and C. R. Penn. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob. Agents Chemother. 36:202-205 (1992).
8. Lisignoli, G., A. Facchini, L. Cattini, M. C. G. Monaco, A. Degrassi, and E. Mariani. In vitro toxicity of 2′,3′-dideoxy-3′-thiacytidine (BCH189/3TC), a new synthetic anti-HIV-1 nucleoside. Antiviral Chem. Chemother. 3:299-303 (1992).
9. Schinazi, R. F., C. K. Chu, A. Peck, A. McMillan, R. Mathis, D. Cannon, L.-S. Jeong, J. W. Beach, W.-B. Choi, S. Yeola, and D. C Liotta. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob. Agents Chemother. 36:672-676 (1992).
10. Sommadossi, J.-P., R. F. Schinazi, C. K. Chu, and M.-Y. Xie. Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human hone marrow progenitor cells. Biochem. Pharmacol. 44:1921-1925 (1992).
11. De Clercq, E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:155-169 (1993)
12. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, Jr., E. A. Emini, and M. E. Goldman. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892 (1991).
13. Richman, D., C.-K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245 (1991).
14. Mellors, J. W., G E. Dutschman, G.-J. Im, E. Tramontano, S. R. Winkler, and Y.-C. Cheng. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451 (1992).
15. Balzarini, J., A. Karlsson, M.-J. Pérez-Pérez, M.-J. Camarasa, and E. De Clercq. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196:576-585 (1993).
16. Balzarini, J., A. Karlsson, M.-J. Pérez-Pérez, M.-J. Camarasa, W. G. Tarpley, and E. De Clercq. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:5353-5359 (1993).
17. Balzarini, J., A. Karlsson, V. V. Sardana, E. A. Emini, M.-J. Camarasa, and E. De Clercq. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K) RT HIV-1 mutants or select for highly resistant (Y181C → C181I) RT HIV-1 mutants. Proc Natl. Acad. Sci USA 91:6599-6603 (1994).
18. Balzarini, J., J.-P. Kleim, G. Riess, M.-J. Camarasa, E. De Clercq, and A. Karlsson. Sensitivity of (138 Glu → lysine) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun. 201:1305-1312 (1994).
19. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine J. Virol. 66:7128-7135 (1992).
20. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234 (1993).
21. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′:3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392 (1993).
22. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881 (1993).
23. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl Acad. Sci. USA 90:5653-5656 (1993).
24. Camarasa, M.-J., M.-J. Pérez-Pérez, A. San-Felix, J. Balzarini, and E. De Clercq. 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′:5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo- and -ribofuranose]-3′-spiro-5′-[4′-amino-1′,2′- oxathiole 2′,2′-dioxide] (TSAO) pyrimidine nucleosides. J. Med. Chem. 35:2721-2727 (1992).
25. Pérez-Pérez, M. J., A. San-Félix, J. Balzarini, E. De Clercq, and M. J. Camarasa. TSAO analogues: stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethyl)-β-D-ribofuranosyl]-3′ -spiro-5′-(4′-amino-1′,2′-oxathiole 2′,2′-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 35:2988-2995 (1992).
26. Pérez-Pérez, M.-J., A. San-Félix, M.-J. Camarasa, J. Balzarini, and E. De Clercq. Synthesis of [1-[2′,5′-bis-O-(t-butyldimethylsilyl)-β-D-xylo- and β-D-ribofuranosyl]thymine]-3′-spiro-5′-[4′-amino-1′ ,2′-oxathiole-2′,2′-dioxide] (TSAO): novel types of specific anti-HIV agents. Tetrahedron Lett. 33:3029-3032 (1992).
27. Balzarini, J., M.-J. Pérez-Pérez, S. Vélazquez, A. San-Félix, M.-J. Camarasa, E. De Clercq, and A. Karlsson. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Proc. Natl. Acad. Sci. USA 92:5470-5474 (1995).
28. Balzarini, J., H. Jonckheere, W. A. Harrison, D. C. Dao, J. Anné, E. De Clercq, and A. Karlsson. Oxathiin carboxanilide derivatives, a class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors (NNETIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem. Chemother. 6:169-178 (1995).
29. Balzarini, J., W. G. Brouwer, E. E. Felauer, E. De Clercq, and A. Karlsson. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res. 27:219-236 (1995).
30. Larder, B. A., S. D. Kemp, and P. R. Harrigan. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (Washington D. C.) 269:696-699 (1995).
31. Schapiro, J. M., M. Winters, and T. C. Merigan. Mutational analysis of the saquinavir high dose monotherapy study, in Abstracts of the Fourth International Workshop on. HIV Drug-Resistance. Sardinia, Italy, 73 (1995).
32. Havlir, D. V., V. A. Johnson, D. B. Hall, P. A. Robinson, C. B. Overbay, and D. D. Richman. Factors determining sustained antiviral response to nevirapine, in Abstracts of the Fourth International Workshop on HTV Drug-Resistance. Sardinia, Italy, 22 (1995).